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Investigation of Microbe and Host Tissue
Interactions Contributing to the Pathogenesis of
Colorectal Cancer
Ryan Chapman, Dhundy Bastola

Abstract—Colorectal cancer (CRC) is one of the leading causes
of cancer-related death worldwide. The pathogenesis of this
disease can fall under broad categories; however, the specific
precursory mechanism of CRC pathogenesis is still unknown.
Dysregulations of the gut microbiome have been identified in
the CRC tissue environment. Additionally, CRC tissue gene
expression has been observed to differ from that of healthy
tissue. Despite these noticeable changes, few studies have directly
compared the microorganism composition to the gene expression
of CRC tissue. Doing so may identify whether the differentially
abundant microorganisms influence the changes in gene expression. The goal of this study is to utilize bioinformatics to identify
enriched microorganism populations as well as differentially
expressed genes within CRC tissue samples to explore the
potential interactions leading to disease pathogenesis. The results
of this study found that populations of toxin-producing bacteria
as well as oral bacteria are present within the CRC tissue
environment. Additionally, changes in gene expression suggest
that these bacteria may be causing an inflammatory immune
response, which could catalyze tumorigenesis.

I. I NTRODUCTION
Colorectal cancer (CRC) is a highly prevalent subtype of
cancer and is the second and third most diagnosed subtype in
women and men, respectively [1]. Each year, around 600,000
individuals die from CRC, making it the most common cause
of cancer-related death worldwide [2]. CRC can arise through
chronic inflammation of the colon, known as colitis-associated
colorectal cancer (CAC), or through a spontaneous mutation
in colon cells, known as sporadic colorectal cancer (SCC) [3].
A mutation in the APC gene, a known tumor suppressor gene,
has been identified as the cause of SCC, and TP53, another
tumor suppressor gene, has been found to be commonly
mutated in CAC [4], [5]. Though the specific genetic mutations
involved in the pathogenesis of CRC are known, precursory
events that lead to these mutations are still being discovered.
Numerous factors have been found to play a role in the development of CRC including diet and intrinsic factors dependent
on the affected individual [6]. Further elucidating these factors
can improve the ability to diagnose, treat, and prevent CRC.
Additionally, these mechanisms may also provide insight into
the pathogenesis of other cancer subtypes.
A. Microbiome Dysregulation in CRC
Recently, the effect of the gut microbiome on the tumorigenesis of CRC has been investigated. It is known that the human
microbiome is important in maintaining a healthy physiology
[6]. Additionally, dysregulation of the gut microbiome has

been found to play a role in allergy, obesity, and type 2
diabetes as well as diseases such as irritable bowel syndrome
(IBS) and gastric cancer [7], [8]. In the case of gastric cancer,
a direct link between the microbe Helicobacter pylori and
the development of the disease has been observed [8]. It is
hypothesized that changes in the microbiome and the mucosa
layer of the colon affect one another, likely playing a role
in the development of CRC [3]. Several organisms have been
found to be enriched in the CRC microbiome.
1) Fusobacterium Nucleatum: Studies by Kostic et al., Viljeon et al., Gao et al., Castellarin et al., Wang et al, Sakamoto
et al., Périchon et al, and Yu et al. found higher levels of
bacteria belonging to the genus Fusobacterium present in colorectal cancer samples, specifically the species Fusobacterium
nucleatum [9]–[16]. Outside of these instances, F. nucleatum
has been found to be associated with various forms of tissue
inflammation, including in GI-related diseases [12]. Kostic et
al., also found that F. nucleatum accelerated the growth of
tumors in mice and caused a pro-inflammatory environment
[9]. Additionally, Kostic et al. and Castellarin et al. note that
F. nucleatum is most abundant in the oral cavity suggesting
an association between oral and gut microbiome dysbiosis [9],
[12]. Further supporting this hypothesis, Yu et al. identified
several other oral pathogens, in addition to F. nucleatum, that
were overrepresented in CRC samples including Parvimonas
micra, Peptostreptococcus stomatis, and Solobacterium moorei
[15].
2) Escherichia coli: Viljeon et al., Buc et al., Arthur et al.,
and Bonnet et al. found a higher prevalence of Escherichia
coli in colorectal cancer patients [10], [17]–[19]. Particularly,
cyclomodulin-positive E. coli was noted by Viljeon et al., Buc
et al., and Bonnet et al. Cyclomodulins are toxins that have
been attributed to tumorigenesis and genotoxicity [10], [19].
Specifically, it is thought that changes to the receptors of the
mucosal lining allow for the colonization of cyclomodulinpositive E. coli [17].
3) Streptococcus bovis and galloyticus: Streptococcus bovis and its subspecies have also been found to be abundant in
the microbiome of CRC patients by Wang et al., Boleij et al.,
Abdulamir et al., and Gupta et al. [13], [20]–[22] The subtype
Streptococcus galloyticus is noted to be highly prevalent [16],
[20], [21]. S. bovis is known to promote cell proliferation and
carcinogenesis, pointing to its relevance in CRC progression
[13].
4) Helicobacter pylori: As previously mentioned, Helicobacter pylori is a known cause of gastric cancer. However, it
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has also shown a potential association with CRC [23]. Several
pro-tumor effects are caused by infection with H. pylori, with
changes to the mucosa of digestive organs being a primary
factor in its contribution to tumorigenesis [24]. Though, the
organism’s role and overrepresentation in CRC samples have
been disputed, and a definitive relationship still remains undetermined [25]. A meta-analysis of 14 studies, conducted by
Zumkeller et al., reported that H. pylori infection and CRC had
a 1.4% odds ratio [26]. If an association is found, changes in
the mucosa caused by H. pylori could provide an explanation
for other changes in the gut microbiome composition in CRC
patients.
5) Bacteroides fragilis: The presence of Bacteroides fragilis was found to be upregulated in fecal samples of CRC
patients by Viljoen et al., Wang et al., Périchon et al, and
Toprak et al. [10], [13], [16], [27]. B. fragilis is a normal
inhabitant of the intestinal microbiome, according to Hajishengalis et al. [28]. However, a subgroup of this bacteria, known
as enterotoxigenic B. fragilis (ETBF), has been found to be
associated with inflammatory disease of the digestive tract
[29]. Toprak et al., specifically, found EBTF to be more
abundant in CRC patient samples [27]. ETBF produces a
toxin that has been suggested to lead to inflammation in the
tissue. A study by Wu et al. found that EBTF colonization
led to tumorigenesis in mice through a TH17-related immune
response [30]. Specifically, CD4+ T-cells were related to tumor
growth in the mice, suggesting an interaction between ETBF
and the host immune system.
6) Enterococcus faecalis: Wang et al. and Balamurugan
et al. found the bacterium Enterococcus faecalis to be more
prevalent in fecal samples of CRC patients [13], [31]. Though,
the involvement of this bacteria in the regulation of the gut
microbiome is somewhat controversial. E. faecalis has been
reported to have some probiotic effects in the treatment of
bronchitis or the regulation of GI-related dysmotility [32],
[33]. However, E. faecalis has also been found to produce superoxide radicals, which can have damaging effects on cellular
DNA, providing a mechanism for tumorigenesis [34]. A study
by Williamson et al. found that coculturing of collagenaseproducing E. faecalis and murine colorectal carcinoma cells
leads to increased invasion and migration of the cells [35].
They hypothesize that the host tissue and bacteria interact to
degrade the stroma and increase the invasiveness of the tumor.
B. Gene Expression changes in CRC
Similar to the wide variety of mechanistic possibilities
found relating to microorganisms in the gut microbiome,
investigation of host tissue gene expression has suggested a
multitude of potential transcriptomic mechanisms and alterations in CRC. A study by Guo et al. utilized microarray
data to identify differentially expressed genes and pathways
in CRC tissue [36]. Notably, genes relating to both cellcycle regulation and inflammation were identified. The genes
CDK1, CCNB1, CENPE, KIF20A, CCNA2, and MAD2L1
were the top differentially expressed genes relating to the cellcycle [36]. Additionally, the genes CXCL1, CXCL2, CXCL6,
CXCL8, and CXCL12, relating to the CXCL family of ligands,
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were upregulated, implicating inflammatory responses [36].
Similarly, Yan et al. found CDK1, CCNB1, and MAD2L1 to
be upregulated in CRC tumor tissues [37]. Along with these
genes, BUB1B, SOX4, MYC, and CCND1 were also upregulated. A study by Kuo et al. identified the genes FOS, FN1,
PPP1CC, and CYP2B6 as being central to protein-protein
interaction networks containing differentially expressed genes
in CRC tumors [38]. These hub genes implicate processes
such as cell proliferation, transcription regulation, cell cycle,
cytoskeleton reorganization, and inflammation in the development of CRC, similar to the results of Guo et al. and Yan et
al. [38].
While both the transcriptome and the microbiome of CRC
have been studied previously, few studies have considered a
connection between the two, despite implications in experimental findings. Specifically, alterations in genes relating to
metabolism, inflammation, and cytoskeletal reorganization are
particularly interesting as these processes may be directly
affected by microbiome dysbiosis. Our hypothesis is that
dysregulation of the colon microbiome leads to transcriptional
changes in colon tissue, in turn leading to cancer. The goal of
this study is to investigate the differences in both the colon
microbiome and the colon transcriptome between CRC tumor
tissue and adjacent healthy tissue samples. Based on data from
transcriptomic and metagenomic analyses, the functions of the
identified microbes can be compared to the expression of the
CRC tissue to hopefully elucidate a mechanism for dysbiosisrelated tumorigenesis. Characterization of this interaction will
be important in developing newer diagnostic and preventative
methods for CRC.
II. M ETHODS
A. Data Availability
Metagenomic shotgun sequencing data published in a study
by Debesa-Tur et al. was used to conduct a metagenomic
analysis (EBI Accession PRJEB34333) [39]. The dataset consists of 98 tissue samples taken from 49 patients with CRC.
Patients in the study were not consistent in disease stage. Each
patient in the study had one sample of tissue removed from the
tumor and another sample of tissue located in a distant region
of the colon removed to serve as a negative control. DNA
was extracted from the tissue samples and sequenced on an
Illumina NextSeq500 using 150bp paired-end read technology.
RNA-sequencing data collected by Wu et al. (SRA Accession PRJNA387172) was used to assemble the transcriptomic
profile of CRC tissue [40]. This study included 104 tissue
samples from CRC patients at different disease stages. From
each patient, RNA was taken from tumor tissue and adjacent
healthy tissue with the adjacent healthy tissue serving as
the negative control. RNA was sequenced on an Illumina
NextSeq500.
B. Metagenomics Analysis
Quality control and trimming of the metagenomic samples was conducted using FastQC and Trimmomatic version
0.11.9 and 0.39, respectively [41], [42]. A sliding window
approach was used to remove regions of the reads with a
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PHRED quality of less than 20, and adapter sequences were
removed from the reads. Finally, any reads that fell below
a minimum length threshold of 50bp were removed. Next,
human DNA contamination was removed by aligning of the
reads to the Human genome using bowtie2 version 2.4.5 [43].
The GRCh38.p14 release of the human genome was used as
the reference (NCBI RefSeq Accession: GCF 000001405.40).
Taxonomic classification and metabolic pathway analysis of
the metagenome was performed using the tools MetaPhlAn3
version 3.0.14 and HUMAnN3 version 3.0.0, respectively
[44]. These tools utilize the ChocoPhlAn3 database which
contains unique marker genes from over 90,000 different
bacterial and archaeal organisms. Circular visualizations of
the sample microbiome compositions were created using the
export2graphlan and GraPhlAn tools, versions 0.22 and 1.1.3
respectively [45], [46].

C. Transcriptomic Analysis
To accommodate the large size of the RNA-sequencing
dataset, given the time limitations for the project, 3 subsets
containing 5 random sample pairings were analyzed. Sample
pairings within each subset were randomly selected, and no
sample pairing was analyzed twice. The published data had
already been pre-trimmed; thus, no quality control was required. Transcript alignment and quantification was performed
using Kallisto version 0.48.0, a combined pseudo-alignment
and quantification tool with high accuracy and robust isoform
identification [47]. The most updated ensemble release of the
Human Genome was used as a reference (Ensembl Accession:
GCA 000001405.28).
Next, differential expression analysis of each subset was
conducted using DESeq2 version 1.30.1 [48]. To import the
transcripts into the DESeq2 package, the tximport and Genomic Features packages (versions 1.18.0 and 1.42.3, respectively) were used to map transcripts to genes based on the
ensembl assembly [49], [50]. Upregulated genes were denoted
as genes that had a log2(Fold Change) greater than 0 and
an adjusted p-value less than 0.05. Similarly, downregulated
genes were denoted as genes that had log2(Fold Change) less
than 0 and an adjusted p-value less than 0.05. The differential
expression analysis was performed in relation to the tumor
samples; thus, upregulated and downregulated genes refer to
those in tumor samples. Functional annotation and pathway
analyses were performed on the differentially upregulated
and downregulated genes using the Biomartr and pathfindR
packages, versions 2.46.3 and 1.6.3 respectively [51]–[53].
The EnhancedVolcano package, version 1.8.0, was used to
generate volcano plots representing the distribution of differentially expressed genes within each subset [54]. Differentially
upregulated and downregulated genes between the subsets
were also used to identify a set of common upregulated and
downregulated genes, overall.
All
Code
is
publicly
available
at
https://github.com/rchapman2022/BIOI4980-Senior-ProjectChapman

Fig. 1. Circular phylogenetic trees showing the abundance and relationship
of microorganisms present in A. Tumor tissue B. Adjacent Healthy Tissue.
TABLE I
M ETABOLIC PATHWAYS IDENTIFIED IN CRC TUMOR TISSUE
METAGENOMIC SAMPLES
Metabolic Pathway
coenzyme A biosynthesis I
dTDP-β-L-rhamnose biosynthesis
adenosine ribonucleotides de novo biosynthesis
dTDP-N-acetylthomosamine biosynthesis

Species Associated
None
Bacteroides cellulosilyticus, Bacteroides fragilis
Bacteroides fragilis, Bacteroides thetaiotaomicron
Bacteroides fragilis

III. R ESULTS
A. Metagenomic Taxonomic Classification
Taxonomic classification using the MetaPhlAn3 software
identified a diverse population of microorganisms present in
the CRC tumor tissue compared to adjacent healthy tissue
(Figure 1A and 1B). A larger population of organisms
in the genus Bacteroides are observed in the tumor tissue
microbiome, including B. fragilis. Additionally, organisms of
the genus Fusobacterium, including F. nucleatum, are found
exclusively in the tumor tissue microbiome.
B. Microbiome Metabolic Pathway Analysis
Several metabolic pathways were identified by HUMAnN3
to be enriched in CRC tumor tissue compared to healthy tissue
(Table 1). Pathways identified were primarily associated with
species in the genus Bacteroides.
C. Host Tissue Differential Expression Analysis
Differential expression was performed separately for each
subset analyzed, and the top differentially upregulated genes
(Figure 2A-C) and downregulated genes (Figure 3A-C) for
each subset were identified. Lists of common differentially
upregulated and downregulated genes were then compiled
through the overlap of these three subsets (Tables 2 and 3).
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TABLE II
T OP 10 COMMON UPREGULATED GENES AMONG THE THREE SUBSETS

Gene Name
KLK6
REG1B
REG1A
CLDN2
FOXQ1
WNT2
PAH
EN2
FGB
DPEP1

Log2(Fold
Subset 1
8.437379
10.68007
10.94704
7.279824
6.806735
7.187942
9.208053
8.695967
5.131777
6.680126

Change)
Subset 2
12.39904
9.459354
9.544892
7.20779
7.142049
5.361155
5.367758
5.813924
9.302612
6.792719

Subset 3
12.50286
8.442904
8.024177
8.32882
8.21668
8.861862
6.700507
6.573458
6.57919
7.410364

Average
11.11309
9.527442
9.505371
7.605478
7.388488
7.136986
7.092106
7.027783
7.004526
6.96107

Genes were sorted by Average Log2(Fold Change) between the three subsets.
Genes without a gene name were not included. All individual Log2(Fold
Change) values are statistically significant (** adjusted p-value < 0.05).
Fig. 2. Distribution of differentially upregulated genes in CRC tissue for A.
Subset 1, B. Subset 2, and C. Subset 3. The top 10 differentially upregulated
genes based on Log2(Fold Change) are labeled for each subset.

TABLE III
T OP 10 COMMON DOWNREGULATED GENES AMONG THE THREE SUBSETS

Gene Name
OTOP2
MYOC
AQP8
NPM1P25
BEST4
CA7
CA1
MT1M
PI16
GUCA2B

Log2(Fold
Subset 1
-6.62933
-7.49499
-5.93522
-6.19772
-5.67734
-5.67219
-4.80864
-5.74548
-5.54374
-4.93464

Change)
Subset 2
-5.82574
-7.77593
-5.25344
-8.33165
-5.61269
-5.66319
-4.94489
-5.00503
-5.18076
-4.3947

Subset 3
-11.6584
-4.78106
-8.63064
-4.82793
-7.65452
-7.20415
-7.78172
-6.30886
-5.75746
-7.05959

Average
-8.03782
-6.68399
-6.60643
-6.45243
-6.31485
-6.17984
-5.84508
-5.68645
-5.49398
-5.46297

Genes were sorted by Average Log2(Fold Change) between the three subsets.
Genes without a gene name were not included. All individual Log2(Fold
Change) values are statistically significant (** adjusted p-value < 0.05).

Fig. 3. Distribution of differentially downregulated genes in CRC tissue
for A. Subset 1, B. Subset 2, and C. Subset 3. The top 10 differentially
downregulated genes based on Log2(Fold Change) are labeled for each subset.

None of the subsets have any top 10 differentially upregulated
or downregulated genes in common.

D. Host Tissue Pathway Analysis
Based on the differentially expressed genes in each subset,
a pathway analysis was performed. The top 15 enriched
pathways were identified for each subset (Figure 4A-C).
Between the three subsets, there is diversity in the pathways
enriched, though there are common pathways. These include
Oxidative Phosphorylation, Cell Cycle, Chemical Carcinogenesis – reactive oxygen species, Nucleocytoplasmic Transport,
Prion disease, Ribosome biogenesis, Thermogenesis, Ubiquitin
mediated proteolysis, and others.

Fig. 4. Enrichment plots depicting pathways found to be enriched based
on differentially expressed genes in A. Subset 1 B. Subset 2 C. Subset 3.
Differentially expressed genes with an adjusted p-value less than 0.05 were
included in the pathway analysis.
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IV. D ISCUSSION
Consistent with the literature, this study identifies differences in both the microbiome composition and host tissue
gene expression between CRC tumor and normal tissue.
Moreover, the CRC tissue and healthy tissue samples analyzed are paired suggesting localized changes in microbiome
composition within the same patient. Regional differences in
microbiome composition have been reported in the literature,
as well. A study by Amos et al. found that, amongst different inflammatory bowel diseases, the microbiome changed
depending on disease location [55]. As well, a study by
Lkhagva et al. observed diversity throughout the entire GI
tract of mice [56]. It may be the case that GI-related diseases,
including CRC, differ in microbiome-related pathogenesis
based on disease location, and future studies could benefit
from investigating location-specific microbiome variations in
CRC tissues.
The CRC tissue samples were found to have a much greater
diversity of microorganisms than the adjacent healthy tissue.
Amongst these microorganisms are several which have been
found to be associated with CRC as well as other diseases.
F. nucleatum has been found previously to be associated with
CRC as well as other diseases such as periodontitis [57]. The
bacterium does not produce any known toxins, although, in
the case of periodontitis, it is known to aid other organisms
in exacerbating the disease [57]. Additionally, it is known to
be highly invasive to host cells [57]. Perhaps, F. nucleatum
is involved in recruiting and developing the microorganism
population capable of tumorigenesis.
The idea of F. nucleatum recruiting pathogenic organisms
is further supported by the presence of additional oral microorganisms. Propionibacterium acidifaciens, another oral
pathogen in the CRC tumor samples, has been found in
one study to cause tooth decay [58]. Another bacterium,
Oribacterium parvum, was present in dental plaques and is
known to produce different lipids [59]. Provotella nigrescens
was also identified in the CRC tissue samples. In addition to
being found in the oral cavity, experiments have suggested that
P. nigrescens is associated with an inflammatory response in
cystic fibrosis tissue [60], [61]. Filifactor alocis is a bacterium
associated with periodontal disease and was also found in the
CRC tissue samples [62]. Interestingly, this bacterium is able
to survive in environments with oxidative stress and was found
to elicit an inflammatory response from macrophages [63].
Taken together, it appears to F. nucleatum may recruit a variety
of microorganisms from the oral microbiome that interact with
the host tissue to promote tumorigenesis.
B. fragilis was also identified, along with several other
organisms of the genus Bacteroides, in the CRC tumor tissue sample. Three of these species were identified in the
adjacent healthy tissue. This finding is not surprising, as the
Bacteroides genus is abundant in the gut microbiome and
provides many beneficial functions [64]. Though, B. fragilis
is known to be associated with CRC, specifically Enterotoxic B. fragilis (EBTF) [64]. This study was not able to
differentiate EBTF, though it is notable that B. fragilis was
only found in the CRC tissue samples. Additionally, two of
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the microorganism metabolic pathways identified in the CRC
tissue samples, dTDP-β-L-rhamnose biosynthesis and dTDPN-acetylthomosamine biosynthesis, were related to B. fragilis.
Both molecules are carbohydrates, which may allow B. fragilis
to evade the host immune system, as Bacteroides are able to
modify their surface polysaccharides [65].
Results of the gene expression analysis suggest that the
CRC tumor tissue is reacting to some sort of physical and
immunological stress, potentially caused by the microbiome.
Among the differentially upregulated genes, several have been
found in literature to be upregulated in different types of
cancer and inflammatory bowel diseases including KLK1,
REG1A, REG1B, WNT2, and EN2 [66]–[70]. Similarly, the top
downregulated genes appear to be general markers associated
with the prevention of cancer progression and inflammatory
bowel disease, making their downregulation significant. These
genes include OTOP2, APQ8, CA7, MT1M, and GUCA2B
[71]–[75]. Among these genes, GUCA2B has been recently
identified as a hub-gene for CRC pathogenesis, with miRNA
targeting this gene found to be upregulated in CRC [75]. The
gene BEST4 was downregulated in these results, but identified
in a study by He et al. to be upregulated in CRC [76]. The
study notes that BEST4 is important to the activation of the
Akt signaling pathway involved in cell proliferation [76]. Thus,
the downregulation of BEST4 suggests unregulated cellular
proliferation. Another gene, CA1, was identified in a study by
Zheng et al. to be associated with the calcification of breast
cancer [77]. Although it was noted as a potential oncogene in
breast cancer, its downregulation may suggest that the tumor
tissue is trying to prevent additional environmental stress.
Several genes, in addition to being associated with cancer
progression, were related to immune cell recruitment and
response. One of these genes, FOXQ1, is associated with
the recruitment of tumor-associated macrophages [78]. While
this type of macrophage has been associated with several
types of cancers, including gastric cancer, the mechanism
that initiates the promotion these cells is unknown [78].
Perhaps, microbiome dysbiosis plays a role in initializing the
recruitment of these immune cells. Additionally, one of the
previously mentioned bacterium in CRC tissue, F. alocis, was
found to elicit a macrophage-related immune response [63].
Additionally, DPEP1, found to be differentially upregulated
in all three samples, has been associated with neutrophil
recruitment in both the liver and the lungs [79]. Like the
macrophage responses related to FOXQ1, dysbiosis may lead
to the recruitment of neutrophils, in turn, leading to the
inflammatory and tumorigenic environment indicated by gene
expression.
Most interesting is the upregulation of the FGB gene,
which has been associated with the presence of oral pathogens
in the aorta of mice [80]. F. nucleatum was among the
pathogens identified in the aorta, however, FGB was found to
be downregulated in this instance [80]. FGB is related to blood
clotting, which suggests that the tissue may be directly reacting
to damage caused by pathogens or general inflammation. The
idea of tissue damage is further suggested by the upregulation
of the CLDN2 gene, which is associated with epithelial tight
junctions [81]. It is possible that the tissue is responding
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to the invasiveness of the microorganisms in the area by
strengthening its epithelial barrier.
Though, among the upregulated and downregulated genes
between subsets, the top genes in each subset were noticeably
absent in the others. While this may appear troubling, this does
support the fact that CRC tumors are heterogeneous in their
gene expression, making a single unified picture difficult to
obtain. Another explanation for this heterogeneity is the fact
that the tumor samples came from patients in various stages of
the disease. The heterogeneity of the tumors does, to a certain
extent, elicit some support for the genes identified between all
three subsets as being common to tumorigenesis. Similarly,
the enriched pathways showed some degree of homogeneity
as well as a relation to the general progression of cancer.
However, enrichment of the chemical carcinogenesis - reactive oxygen species pathway supports the overall suggested
mechanisms. Reactive oxygen species are an important factor
in inflammatory diseases and are not effective against some
oral pathogens found in the CRC tissue samples including, F.
alocis [82].
V. C ONCLUSION
Altogether, the results of this analysis suggest microbiome
dysbiosis is occurring in CRC tissue. This dysregulation was
characterized as having an increase in oral pathogens, possibly
induced by the bacterium F. nucleatum, as well as an increase
in a previously identified bacterium related to CRC, B. fragilis.
Investigation into gene expression provided potential mechanisms by which these oral pathogens can influence tumorigenesis: through the triggering of an inflammatory immune
response as well as tumor tissue damage response. Although
no discrete connections could be made, these suggestions
do hold some merit and should be further investigated in
subsequent studies.
VI. L IMITATIONS
There are several limitations to this study that contribute to
the inconclusively of the data. These factors would have been
controlled for or corrected had this study not been limited by
the timeline of an undergraduate thesis. One major limitation is
the fact that the metagenomic and transcriptomic datasets were
not taken from the same patient and the fact that disease stage
was not controlled for. Ideally, both metagenomic DNA and
RNA samples should have been taken from the same patient.
However, for the purposes of this study, the fact that both
studies consisted of paired tumor and healthy tissue samples
was sufficient to make a connection.
Another limitation of this study was the inability to analyze
the entire transcriptomic dataset. The server available for this
analysis is utilized by the UNO Bioinformatics department and
was not large enough to store all of the intermediate data and
results. To make up for this, three subsets of 5 paired samples
were analyzed and the results were compared.
One final limitation is the quality of the metagenomics
dataset. In each sample, > 90% of the reads were human
contamination, and many samples showed no organism classification. The publication that the data was derived from
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corroborates this. Newer metagenomic analysis tools were
employed to see if the results could have been improved, but
this was not the case. Thus, the metagenomic data is likely
only a small portion of a larger population of organisms.
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